adeno-associated virus vector AAV- CNGA3

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Achromatopsia

Conditions

Achromatopsia

Trial Timeline

Aug 12, 2019 → Jun 10, 2021

NCT ID

NCT03758404

About adeno-associated virus vector AAV- CNGA3

adeno-associated virus vector AAV- CNGA3 is a phase 1/2 stage product being developed by MeiraGTx for Achromatopsia. The current trial status is completed. This product is registered under clinical trial identifier NCT03758404. Target conditions include Achromatopsia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03758404	Phase 1/2	Completed	Aug 12, 2019	Jun 10, 2021	Achromatopsia

Competing Products

2 competing products in Achromatopsia

See all competitors

Product	Company	Stage	Hype Score
AAV - CNGB3	MeiraGTx	Phase 1/2	26
Prior exposure to AAV-CNGA3 or AAV-CNGB3	MeiraGTx	Pre-clinical	12